{
    "domain": "medicine",
    "concept": "approved drug for skin cancer",
    "definition": "A drug approved to treat skin cancer",
    "selection_criteria": [
        "it is a drug",
        "it has been approved to treat skin cancer"
    ],
    "referents_source": "https://www.cancer.gov/about-cancer/treatment/drugs/skin",
    "referents": [
        "5-FU (Fluorouracil--Topical)",
        "Aldara (Imiquimod)",
        "Aldesleukin",
        "Avelumab",
        "Bavencio (Avelumab)",
        "Binimetinib",
        "Braftovi (Encorafenib)",
        "Cemiplimab-rwlc",
        "Cobimetinib",
        "Cosibelimab-ipdl",
        "Cotellic (Cobimetinib)",
        "DTIC-Dome (Dacarbazine)",
        "Dabrafenib",
        "Dacarbazine",
        "Efudex (Fluorouracil--Topical)",
        "Encorafenib",
        "Erivedge (Vismodegib)",
        "Fluorouracil--Topical",
        "IL-2 (Aldesleukin)",
        "Imiquimod",
        "Imlygic (Talimogene Laherparepvec)",
        "Interleukin-2 (Aldesleukin)",
        "Intron A (Recombinant Interferon Alfa-2b)",
        "Ipilimumab",
        "Keytruda (Pembrolizumab)",
        "Kimmtrak (Tebentafusp-tebn)",
        "Libtayo (Cemiplimab-rwlc)",
        "Mekinist (Trametinib Dimethyl Sulfoxide)",
        "Mektovi (Binimetinib)",
        "Nivolumab",
        "Nivolumab and Relatlimab-rmbw",
        "Odomzo (Sonidegib)",
        "Opdivo (Nivolumab)",
        "Opdualag (Nivolumab and Relatlimab-rmbw)",
        "Pembrolizumab",
        "Proleukin (Aldesleukin)",
        "Recombinant Interferon Alfa-2b",
        "Retifanlimab-dlwr",
        "Sonidegib",
        "Tafinlar (Dabrafenib)",
        "Talimogene Laherparepvec",
        "Tebentafusp-tebn",
        "Trametinib Dimethyl Sulfoxide",
        "Unloxcyt (Cosibelimab-ipdl)",
        "Vemurafenib",
        "Vismodegib",
        "Yervoy (Ipilimumab)",
        "Zelboraf (Vemurafenib)",
        "Zynyz (Retifanlimab-dlwr)"
    ]
}